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There are no comprehensive guidelines for metastatic screening for newly diagnosed patients in 
South Africa (SA), although the 2018 National Breast Health Policy (which is still to be finalised 
and formally adopted) will provide some guidance. This article aims to review the most recent 
literature and international guidelines with consideration given to best practice in SA, both in the 
public and private sectors.
Globally, breast cancer is the most prevalent cancer affecting women and the incidence in 
low-middle income countries (LMICs) is predicted to rise as life expectancy increases.1 The stage 
at the time of presentation differs between high-income countries (HICs) and LMICs. In the 
United States, between 35% (uninsured population) and 76% (insured population) of women, 
aged between 50 and 74 years, had a mammogram in the preceding 2 years. This contrasts with 
figures from a 2003 World Health survey where only 2.2% women in LMICs aged 40–69 received 
any breast screening.2,3
While accurate statistics are not available for SA, it is estimated that between 50% and 60% of 
women present with locally advanced or metastatic breast cancer.4,5 This figure compares 
unfavourably to those from HICs (many of whom have population-based screening programmes) 
where approximately 5% of women present with the metastatic disease.6
Staging, as defined by the American Joint Committee on Cancer (AJCC), has historically been 
limited to anatomical staging. While the eighth version of the AJCC guidelines7 has been altered 
to include tumour biology, anatomical staging still holds a place, as it allows for population 
studies, provides a concise summary of the patient, gives an indication of tumour biology, permits 
comparative population-based studies and guides treatment. However, some controversy exists 
Background: Staging for breast cancer patients, as defined by the American Joint Committee 
on Cancer (AJCC), has historically been limited to anatomical staging. However, the eighth 
version of the AJCC guidelines has been altered to include tumour biology. Anatomical 
staging still has a place especially in low-middle income countries where the majority of 
patients present with locally advanced or metastatic disease.
Aim: This review article considers which newly diagnosed breast cancer patients should be 
referred for anatomical staging and the pros and cons of the different modalities available in 
South Africa.
Method: The different modalities available were reviewed with respect to metastatic screening 
for asymptomatic women. The usefulness of the modalities were considered with reference to 
organ-specific disease rather than the stage of the patient. 
Results: Any person with newly diagnosed breast cancer and symptoms suggestive of systemic 
involvement should be investigated. All symptomatic women who present with a tumour 
larger than 5 cm, radiological or clinical evidence of nodal disease, triple negative or HER2+ve 
tumours should have metastatic screening. This gives information about the primary as well 
as the metastatic status. 
Conclusion: However, increasingly, the major determinant of treatment is the biology of the 
cancer and not the anatomical stage. In future, this trend is likely to increase with anatomical 
staging becoming less important. 
Keywords: breast cancer; metastatic disease; screening; guidelines; best practice; review.
Metastatic screening for patients with newly 
diagnosed breast cancer: Who and how? 
Copyright: © 2020. The Authors. Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License.
Page 2 of 6 Review Article
http://www.sajo.org.za Open Access
with the diagnosis of metastatic disease. Traditionally, stage 
IV disease has been defined as incurable but not untreatable. 
However, because of increased definition of imaging 
modalities, a number of patients are diagnosed with low-
volume oligometastatic disease. Although technically 
classified as a stage IV disease, it may, in some instances, be 
curable.
Who should undergo metastatic 
screening? 
Most guidelines agree that patients who present with 
symptoms that could be attributable to metastatic spread 
should be investigated. However, there is an ongoing debate 
about which asymptomatic patients should have systemic 
screening and what modality should be used. Overall, the 
detection of metastatic disease is 1% – 16%.8 The likelihood 
of finding metastatic disease increases with the clinical stage 
at presentation and is dependent on the modality used. Six 
per cent of patients with clinically determined stage IIb 
disease are upgraded to stage IV, as are 14% – 25% of those 
clinically presenting with stage III of the disease.6 The 
National Comprehensive Cancer Network (NCCN) and 
European Society of Medical Oncologists (ESMO) both 
recommend metastatic screening for all patients with a 
cancerous lesion or tumour > 5 cm in size and clinical or 
radiological nodal metastases. 9,10
There are several subgroups of patients with early breast 
cancer who should also be considered for metastatic 
screening. Patients with triple-negative disease are known 
to have a higher chance of visceral metastases, and some 
authors have suggested that patients less than 40 years 
should be considered separately.11
The following arguments against metastatic screening for 
all are well-documented:
• The cost involved. 
• Oligometastatic disease (low-volume metastatic disease). 
As imaging modalities have become more advanced, 
smaller lesions are detected. The oligometastatic disease 
may, in some instances, be curable. Defining these women 
as being affected with stage IV of the disease may result 
in them no longer being treated with an intention to cure, 
thereby denying them the chance of cure. However, the 
detection of even low-volume metastatic disease may 
change the management approach. 
• Anxiety to the patient and the family.
The balance between cost, availability of local resources and 
benefit from anatomical screening in women 
newly diagnosed with breast cancer continues to be 
debated. While international guidelines differ in specific 
recommendations, all agree that any symptomatic woman 
should have relevant metastatic screening and that there is 
no role for metastatic screening in asymptomatic women 
with early breast cancer. The National Institute for Health 
and Care Excellence (NICE) guidelines recommend staging 
for asymptomatic patients presenting with symptoms related 
to stage III and above but are vague regarding what modality 
should be used.12 This prompted a survey to be carried out by 
the Association of British Surgeons (ABS) asking breast care 
units about their practices. They found poor consistency 
amongst the 123 recipients as to who should be screened. 
Interestingly, the modalities available were chest X-ray (CXR) 
(99%), computed tomography (CT) scan (99%), magnetic 
resonance imaging (MRI) (95%), liver ultrasound (US) 
(100%), bone scan (10%) and positron emission tomography-
CT (PET-CT) scan (57%).13
What modalities should be used for 
screening?
The different modalities available will be reviewed with 
respect to metastatic screening for asymptomatic women. 
The usefulness of the modalities will be considered with 
reference to organ-specific disease rather than the stage of 
the patient.
Chest X-ray
The lung is not a common site of metastatic disease detected 
with CXR. According to the pooled prevalence in studies 
performed after 1998, 25/2258 patients (1.1%) had lung 
metastases (Table 1). Only two studies have reported CXR 
results by stage of the disease.8,14 Data were collected 
retrospectively in both studies. A CXR was performed before 
surgery in one study and after surgery in the other.15 The 
pooled prevalence of distant metastases in stage I of the disease 
was 0.1% and 1.7% in stage III of the disease, with an overall 
prevalence of 0.5%. Barret et al.16 stated that preoperative CXR 
is not used as a staging investigation, and this recommendation 
is supported by the latest ESMO guidelines.10
Bone scan
The bone scan is commonly used for detecting bone metastases 
in patients with breast cancer. The detection rate of a bone 
scan for skeletal metastases is more sensitive than skeletal 
radiographs.20 Although sensitivity rates as high as 98% have 
been reported,21 the most recent meta-analysis investigating 
bone scan reported a sensitivity of 81% (95% confidence 
interval [CI]: 58% – 93%) and a specificity of 96% (95% CI: 
76% – 100%).22 The overall pooled prevalence of bone 
metastases is low in studies conducted after 1998 (Table 2). 
The pooled prevalence of distant bone metastases was 
258/10 241 (2.5%). Similar to lung metastases, bone metastases 
are more common in more advanced disease. Myers et al.23, in 
TABLE 1: Prevalence of lung metastasis in all stages of disease as detected by 
chest X-ray.






Ravaioli et al.17 1998 1218 8 1206 0.7
Barry et al.18 1999 82 1 79 1.2
Dillman and Chico8 2000 947 12 545 2.2
Puglisi et al.19 2005 412 4 428 0.9
All studies - - 25 2258 1.1
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their meta-analysis, reported a pooled prevalence ranging 
from 0.5% in stage I of the disease to 8.3% in stage III of the 
disease, with an overall prevalence of 3.1%.
Liver ultrasound
The liver is less frequently involved than bone and liver 
metastases, and in asymptomatic patients, it is quite rare. 
Myers et al.23 reported a pooled prevalence ranging from 0% 
in stage I of the disease to 2% in stage III of the disease, 
with an overall prevalence of 0.6%. The pooled prevalence 
in data published after 1998 was 0.9% (23/2404) (Table 3).
Computed tomography scan
Computed tomography scan has the advantage of being 
fast and reliable, and it allows for the assessment of the 
lungs, liver and bone in a single investigation. It is the 
primary screening modality used in the United Kingdom.13 
The limitations of CT scan are the need for adequate 
renal function and patients being subjected to radiation. 
Computed tomography scan is sensitive for the detection 
of lung and liver metastases (75% – 100%), with relatively 
good specificity (91% – 98%).16,27,28 The area of controversy 
for its use as a single imaging investigation for women 
with breast cancer has been its reliability in the detection 
of bone lesions. McCartan et al.29 reviewed the results of 
screening 631 breast cancer patients with both a bone 
scan and a CT scan and determined that 69 patients 
had metastatic disease and 39 had bone metastases. All 
but two of the patients with bone metastases had axial 
involvement, which was detected on the CT scan.
In LMICs where locally advanced breast cancer is 
commonplace, the question of surgical resectability is often 
problematic. The CT scan has the added advantage of 
providing good definition of the soft tissue and so provides 
valuable information when considering the resectability 
of tumours and the degree of local infiltration into the chest wall.
Whole body magnetic resonance imaging 
screening for metastases
Whole body MRI (WBMRI) is emerging as a valuable imaging 
solution to screen for metastases in cancer patients, including 
breast cancer. Imaging with WBMRI aims to screen for 
metastatic involvement of regional and distant sites. Skeletal, 
nodal, visceral and soft tissue metastases can be identified, 
with varying degrees of accuracy.30,31,32,33
Several studies have assessed the performance of WBMRI 
as a screening tool versus conventional and specialised 
modalities (e.g. CT, bone scintigraphy, PET, PET-CT). These 
studies have highlighted the favourable performance of 
WBMRI, certain shortcomings and accuracy spectrum 
depending on the anatomical site of involvement.
The protocol for WBMRI is not standardised between 
institutions, and this has a significant effect on the results 
of trials and meta-analyses. Whole body MRI can be 
performed only as diffusion-weighted whole body 
imaging with background body signal suppression 
(DWIBS) or with additional sequences (T1, STIR short tau 
inversion-recovery.
T1, other). Specialised coils can further improve 
performance accuracy and affect trial results. At our 
institution (i.e. Morton and Partners Radiologists), the 
study involves whole body DWIBS, whole body T1 and 
STIR, and dedicated spinal T1 and STIR.
Whole body MRI is a highly accurate modality for the 
detection of skeletal metastases, equalling or outperforming 
bone scintigraphy, fluorodeoxyglucose (FDG) PET and 
PET-CT, with sensitivity and specificity above 90%.29,30 
For liver metastases, WBMRI has comparable performance 
with CT (sensitivity of 92% and specificity of 87%, vs. 93% 
and 96% for CT).32,33 When screening for nodal metastases, 
the accuracy is similar or slightly lower, compared with 
PET-CT and contrasted CT (accuracy 87% vs. 95%).31,32 
Lung metastases screening using only diffusion (DWIBS) 
is inadequate, with high specificity (91%) but only 
33% sensitivity (accuracy 61%).32 With dedicated coils 
and further sequences, the sensitivity can be increased to 
86% for 6 mm – 9 mm lesions and 100% for > 10 mm 
lesions.34
The advantages of WBMRI are as follows:
• True whole-body imaging (including the brain).
• Comparable or better than conventional modalities for 
bone and liver metastases.
• No radiation or intravenous contrast injection.
• Readily available and cost-effective (especially when 
compared with PET-CT).
TABLE 3: Prevalence of liver metastasis in all stages of disease, as detected by 
liver ultrasound.






Ravaioli et al.17 1998 1218 10 1206 0.8
Dillman and Chico8 2000 947 1 226 0.4
Puglisi et al.19 2005 412 3 412 0.7
Kasem et al.26 2006 221 3 221 1.4
Barrett et al.16 2009 2612 6 339 1.8
All studies - - 23 2404 0.9
TABLE 2: Prevalence of bone metastasis in all stages of disease as detected by 
bone scan.






Ravaioli et al.17 1998 1218 37 1193 3.1
Dillman and Chico8 2000 947 20 601 3.3
Koizumi et al.24 2001 5538 118 5538 2.1
Puglisi et al.19 2005 412 26 412 6.3
Lee et al.25 2005 1939 28 1939 1.4
Kasem et al.26 2006 221 6 221 2.7
Barrett et al.16 2009 2612 23 337 6.8
All studies - - 258 10 241 2.5
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The disadvantages include lower sensitivity for lung 
metastases, especially small lesions, and lower accuracy for 
nodal metastases when compared with PET-CT.
Breast cancer histo-molecular subtype characteristics can 
further impact on and personalise the future approach to 
metastatic screening. Skeletal metastases are by far the 
predominant site in luminal A and B tumours and the 
predominant site in Her2+/Hormone Receptor (HR)+, 
Her2+/HR- and triple-negative (TN) non-basal subgroups. 
Visceral and nodal metastases are more prevalent in TN, 
basal-like tumours. These differences may well impact 
decisions pertaining to preferred imaging modality.
Taking accuracy at various metastatic sites and tumour histo-
molecular characteristics into account, the role of WBMRI 
may be:
• Additional to baseline anatomical screening or CT to 
allow future follow-up and problem-solving.
• Assessing the treatment response of systemic disease.
• Follow-up in cancer subtypes at high risk of predominantly 
skeletal metastases.
Fluorine-18 fluorodeoxyglucose positron 
emission tomography-computed tomography
Positron emission tomography combined with sequential 
(X-ray) computed tomography (PET-CT) is most 
commonly performed using fluorine-18 fluorodeoxyglucose 
([F-18]-FDG), a glucose analogue. Because many cancers, 
including most breast cancers, avidly metabolise glucose, 
FDG PET-CT offers a sensitive means to detect malignant 
tissue. Accumulating evidence has recently led to the societal 
endorsement of FDG PET-CT as an alternative to CT and 
bone scan for the baseline staging of advanced breast cancer.35
There is evidence that PET-CT is similarly specific but more 
sensitive than bone scan in the detection of skeletal metastases 
(sensitivity: 93% [82% – 98%] vs. 81% [58% – 93%]; specificity: 
99% [95% – 100%] vs. 96% [76% – 100%]),22 and more sensitive 
than diagnostic CT (chest-abdomen-pelvis) in the detection 
of distant metastatic spread to all sites combined (odds ratio 
[OR] 3.28 [92.37–4.53]).36 There is also support for PET-CT’s 
superior sensitivity (and similar specificity), compared to 
other conventional imaging strategies that combine 
techniques such as CXR or chest CT, and liver ultrasound. 
In a meta-analysis analysing six such comparative studies 
(total of 664 patients), PET-CT was found to be similarly 
specific but more sensitive than conventional imaging in 
identifying metastases to all sites combined (sensitivity: 97% 
[84% – 99%] vs. 56% [38% – 74%]; specificity: 95% [93% – 97%] 
vs. 91% [78% – 97%]).37 Positron emission tomography-
computed tomography has also been better studied than 
WBMRI, for which evidence in breast cancer staging, 
although promising, is more limited.
Advantages of FDG PET-CT include the fact that it can 
frequently replace staging strategies that rely on multiple 
imaging tests, that it offers whole body assessment and that 
it is relatively straightforward (and rapid) to interpret. 
Disadvantages of PET-CT include its limited availability, 
high cost and an ionising radiation burden similar in 
magnitude to standalone contrast-enhanced CT chest-
abdomen. Additional drawbacks of PET, such as its relatively 
limited spatial resolution and its lower sensitivity in lobular 
carcinoma subtype because of reduced FDG-avidity, are 
partially mitigated by information obtained from the 
sequentially acquired CT component of the PET-CT.
Recommendations for positron emission 
tomography scan in breast cancer
Early stage
Not recommended as routine for locoregional (early) disease.38
Not recommended as routine in patients presenting with 
clinical stage I, II or operable stage III disease symptoms.39
Late stage
May be considered instead of, and not in addition to, bone scan 
and diagnostic CT in patients with locally advanced disease* 
(level IIB recommendation).35 Positron emission tomography-
computed tomography does not replace sentinel lymph 
node biopsy and axillary node dissection.38
May be considered when conventional imaging is inconclusive 
in patients with locally advanced disease*1, in tumours with 
aggressive biology or in cases of suspected metastatic disease 
(on the basis of signs, symptoms or laboratory values).38,39,40,41
May be considered in addition to bone scan and diagnostic CT in 
patients presenting with clinical stage IIIa (T3N1M0) of 
the disease and for staging of high-risk patients who 
are candidates for neoadjuvant chemotherapy.39 Positron 
emission tomography-computed tomography obviates bone 
scan if skeletal metastases are identified.39
Conclusion
Any person with newly diagnosed breast cancer and 
symptoms suggestive of systemic involvement should be 
investigated. All symptomatic women who present with a 
tumour larger than 5 cm, radiological or clinical evidence of 
nodal disease, triple negative or HER2+ve tumours should 
have metastatic screening. Whilst the modality utilised may 
vary with local availability, the recommendations of the 
authors is for a CT scan of the chest and abdomen. This 
gives information about the primary as well as the metastatic 
status. Although routine bone scan is not recommended if a 
CT scan is done, a bone scan can be added selectively if 
the patient complains of symptoms suspicious of bone 
metastases with a normal CT scan and no other pathology 
to explain the symptoms. The other indication for a bone 
*.Where locally advanced breast cancer is defined by cases with any of the following: 
large tumours (> 5 cm in diameter); tumours that involve overlying skin or underlying 
muscle; involvement of multiple regional lymph nodes; or inflammatory breast 
cancer. 
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scan would be an inconclusive CT scan where the reporting 
radiologist is unsure if the bone pathology seen represents 
metastases. The decreasing cost of newer modalities of 
screening, such as PET-CT scan and WBMRI, makes these 
modalities increasingly accessible, and the majority of 
recent publications on the subject of metastatic screening 
have assessed their utilisation. However, increasingly, the 
major determinant of treatment is the biology of the cancer 
and not the anatomical stage. In future, this trend is likely to 
increase with anatomical staging becoming less important.
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